Genetic Damage Detected in CD-1 Mouse Pups Exposed Perinatally to 3′-Azido-3′-Deoxythymidine and Dideoxyinosine Via Maternal Dosing, Nursing, and Direct Gavage

Environmental and Molecular Mutagenesis

Volumn 43, Issue 1, 2004, Pages 3-9

  Bishop, Jack B ^a   Witt, Kristine L ^a,b   Tice, Raymond R ^b   Wolfe, Gary W ^c  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b INTEGRATED LABORATORY SYSTEMS   (United States)

^c TherImmune Research Corporation   (United States)

Author keywords

Antiretroviral drugs; AZT; Chromosome damage; Micronuclei; Nucleoside analogues; Transplacental exposures

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTIVIRUS AGENT; DIDANOSINE; GENOTOXIC AGENT; TOXIC SUBSTANCE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST FEEDING; CELL PROLIFERATION; CHROMOSOME DAMAGE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE MARKER; DRUG SENSITIVITY; ERYTHROCYTE; FEEDING; FEMALE; GENETIC DAMAGE; GENOTOXICITY; HEMATOPOIETIC STEM CELL; LACTATION; MATING; MICRONUCLEUS; MOUSE; MOUSE STRAIN; NONHUMAN; PERINATAL DRUG EXPOSURE; PERINATAL PERIOD; PREGNANCY; REPRODUCTIVE TOXICITY; RETICULOCYTE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; DIDANOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ERYTHROCYTES; FEMALE; LACTATION; MALE; MICE; MICE, INBRED STRAINS; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; MUTAGENS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TIME FACTORS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0842266655     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/em.10210     Document Type: Article

References (35)

1. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, Dollfus C, Mayaux M-J, Blanche S, for the French Perinatal Cohort Study Group. 2003. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 17:1769-1785.
2. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguere I, Rotig A, Mayaux M-J, Delfraissy J-F. 1999. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354:1084-1089.
3. Bonassi S, Hagmar L, Stromberg U, Montagud AH, Tinnerberg H, Forni A, Heikkilia P, Wanders S, Wilhardt P, Hansteen IL, Knudsen LE, Norppa H. 2000. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res 60:1619-1625.
4. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al. for The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type I with zidovudine treatment. N Engl J Med 331:1173-1180.
5. Cooper ER, Charurat M, Mofenson LM, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W; Women and Infants' Transmission Study Group. 2002. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29:484-494.
6. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, Mofenson LM, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J. 1999. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 281:151-157.
7. Dertinger S, Torous D, Tometsko K. 1996. Induction of micronuclei by low doses of azidothymidine (AZT). Mutat Res 368:301-307.
8. Dertinger S, Torous D, Hall N, Murante F, Gleason S, Miller R, Tometsko K. 2002. Enumeration of micronucleated CD71-positive human reticulocytes with a single-laser flow cytometer. Mutat Res 515:3-14.
9. Diwan BA, Riggs CW, Logsdon D. 1999. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-2′,3′-dideoxythymidine in mice. Toxicol Appl Pharmacol 161:82-99.
10. Hagmar L, Bonassi S, Stromberh U, Mikoczy Z, Lando C, Hansteen IL, Montagud AH, Knudsen LE, Norppa H, Reuterwall C, Tinnerberg H, Brogger A, Forni A, Hogstedt B, Lambert B, Mitelman F, Nordenson I, Salomaa S, Skerfving S. 1998. Cancer predictive value of cytogenetic markers used in occupational health surveillance programs: a report from an ongoing study by the European Study Group on cytogenetic biomarkers and health. Mutat Res 405:171-178.
11. Hayashi M, Sofuni T, Ishidate M Jr. 1983. An application of acridine orange fluorescent staining to the micronucleus test. Mutat Res 120:241-247.
12. Hayashi M, Sofuni T, Ishidate M Jr. 1984. Kinetics of micronucleus formation in relation to chromosomal aberrations in mouse bone marrow. Mutat Res 127:129-137.
13. Heddle JA, Hite M, Kirkhart B, Mavournin K, MacGregor JT, Newell GW, Salamone MF. 1983. The induction of micronuclei as a measure of genotoxicity. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 123:61-118.
14. Hirai O, Miyamae Y, Fujino Y, Izumi H, Miyamoto A, Noguchi H. 1991. Prior bleeding enhances the sensitivity of the in vivo micronucleus test. Mutat Res 264:109-114.
15. Luke CA, Tice RR, Drew RT. 1988. The effect of exposure regimen and duration on benzene-induced bone-marrow damage in mice. Mutat Res 203:25-271.
16. MacGregor JT, Wehr CM, Henika PR, Shelby MD. 1990. The in vivo erythrocyte micronucleus test: measurement at steady state increases assay efficiency and permits integration with toxicity studies. Fundam Appl Toxicol 14:513-522.
17. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, Lachassine E, Barret B, Chaix ML, Bongain A, Ciraru-Vigneron N, Crenn-Hebert C, Delfraissy JF, Fouzioux C, Mayaux MJ, Blanche S; (ANRS) 075 Study Group. 2001. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 285:2083-2093.
18. Meng O, Walker DM, Olivero OA, Shi X, Antiochos BB, Poirier MC, Walker VE. 2000. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 97:12667-12671.
19. Mofenson LM, Munderi P. 2002. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 30:200-215.
20. National Toxicology Program (NTP). 1999. NTP technical report on the toxicology and carcinogenesis studies of AZT and AZT/alpha-interferon A/D in B6C3FI mice (gavage studies). U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
21. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. 1997. Transplacental effects of 3′-azido-2′,3′-dideoxthymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89:1602-1608.
22. Olivero OA, Beland FA, Fullerton NF, Poirier MC. 1994. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3′-azido-2′,3′ -dideoxythymidine. Cancer Res 54:6235-6242.
23. Olivero O, Shearer G, Chougnet C, Kovacs A, Landay A, Baker R, Stek A, Khoury M, Prois L, Kessler H, Sha B, Tarone R, Poirier M. 1999. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS 13:919-925.
24. Olivero OA, Reddy MK, Pietras SM, Poirier MC. 2001. Plasma drug levels compared with DNA incorporation of 3′-azido-3′-deoxythimidine (AZT) in adult cynomolgus (Macaca fascicularis) monkeys. Exp Biol Med 226:446-449.
25. Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St. Claire ME, Poirier MC. 2002. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 29:323-329.
26. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department Health and Human Services and Henry J. Kaiser Family Foundation, Feb 4, 2002.
27. Phillips M, Nascimbeni B, Tice R, Shelby M. 1991. Induction of micronuclei in mouse bone marrow cells: an evaluation of nucleoside analogues used in the treatment of AIDS. Environ Mol Mutagen 18:168-183.
28. Poirier MC, Patterson TA, Slikker W Jr, Olivero OA. 1999. Incorporation of 3″-azido-2′,3′-dideoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. J Acquir Immune Defic Syndr 22:477-483.
29. Public Health Service Task Force Perinatal HIV Guidelines Working Group. 2002. Summary of the updated recommendations from the Public Health Service Task Force to reduce perinatal human immunodeficiency virus-1 transmission in the United States. Obstet Gynecol 99:1117-1126.
30. Robbins WA, Witt KL, Haseman JK, Dunson DB, Troiani L, Cohen MS, Hamilton CD, Perreault SD, Libbus B, Beyler SA, Raburn DJ, Tedder ST, Shelby MD, Bishop JB. 2001. Antiretroviral therapy effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. J Infect Dis 184:127-135.
31. Schlegel R, MacGregor JT. 1982. Persistence of micronuclei in peripheral blood erythrocytes: detection of chronic chromosome breakage in mice. Mutat Res 104:367-369.
32. Sperling RS, Shapiro EE, Coombs RW. 1996. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 335: 1621-1629.
33. Suzuki S, Atai H, Hatakeyama Y, Hara M, Nakagawa S. 1989. Administration-route-related differences in the micronucleus test with benzene. Mutat Res 223:407-410.
34. +/- mice treated neonatally with zidovudine and lamivudine. Carcinogenesis 23:1427-1432.
35. 1 mice from short-term, prechronic, and chronic studies of the NTP carcinogenesis bioassay program. Environ Mol Mutagen 36:163-194